HomeCompareHJLI vs VIG

HJLI vs VIG: Dividend Comparison 2026

HJLI yields 19.27% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HJLI wins by $37.5K in total portfolio value
10 years
HJLI
HJLI
● Live price
19.27%
Share price
$10.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$69.8K
Annual income
$6,227.54
Full HJLI calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — HJLI vs VIG

📍 HJLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHJLIVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HJLI + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HJLI pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HJLI
Annual income on $10K today (after 15% tax)
$1,637.76/yr
After 10yr DRIP, annual income (after tax)
$5,293.41/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, HJLI beats the other by $5,144.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HJLI + VIG for your $10,000?

HJLI: 50%VIG: 50%
100% VIG50/50100% HJLI
Portfolio after 10yr
$51.0K
Annual income
$3,201.37/yr
Blended yield
6.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HJLI right now

HJLI
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
14.9
Piotroski
3/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HJLI buys
0
VIG buys
0
No recent congressional trades found for HJLI or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHJLIVIG
Forward yield19.27%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$69.8K$32.3K
Annual income after 10y$6,227.54$175.21
Total dividends collected$38.9K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HJLI vs VIG ($10,000, DRIP)

YearHJLI PortfolioHJLI Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$12,627$1,926.78$11,301$160.59+$1.3KHJLI
2$15,784$2,273.74$12,752$162.91+$3.0KHJLI
3$19,546$2,656.40$14,370$165.02+$5.2KHJLI
4$23,988$3,074.20$16,176$166.93+$7.8KHJLI
5$29,193$3,526.09$18,188$168.67+$11.0KHJLI
6$35,247$4,010.50$20,432$170.25+$14.8KHJLI
7$42,240$4,525.40$22,933$171.68+$19.3KHJLI
8$50,265$5,068.41$25,720$172.98+$24.5KHJLI
9$59,421$5,636.78$28,827$174.15+$30.6KHJLI
10$69,808$6,227.54$32,288$175.21+$37.5KHJLI

HJLI vs VIG: Complete Analysis 2026

HJLIStock

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.

Full HJLI Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this HJLI vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HJLI vs SCHDHJLI vs JEPIHJLI vs OHJLI vs KOHJLI vs MAINHJLI vs DGROHJLI vs NOBLHJLI vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.